Search - tctmd.com

Displaying 881 - 900 of 1071

Sort: Relevancy | Date

Presentation TCT 2013

Echocardiographic Results in the CoreValve US Extreme Risk Study: Hemodynamics and Aortic Regurgitation

Presenter: Jae Oh

October 29, 2013

News Conference News TCT 2013

Opportunities Exist to Improve Outcomes in Transapical TAVR

October 29, 2013

Presentation TCT 2013

Mitral Regurgitation in Aortic Stenosis: How Often Is Surgical or Transcatheter Aortic Valve Replacement Effective?

Presenter: Howard Herrmann

October 28, 2013

Presentation TCT 2013

Epidemiology and Prognostic Impact of Mitral Regurgitation (and Why Does MR Take a Backseat to Aortic Stenosis?)

Presenter: Maurice Sarano

October 28, 2013

Presentation TCT 2013

Reduces Paravalvular Regurgitation

Presenter: Rebecca Hahn

October 28, 2013

Presentation TCT 2013

Incidence, Predictors, and Outcomes of Paravalvular Regurgitation After TAVR

Presenter: Samir Kapadia

October 28, 2013

Presentation TCT 2013

Endoluminal Sciences: A New Concept for Eliminating Paravalvular Regurgitation

Presenter: Raj Makkar

October 28, 2013

Presentation TCT 2013

Case 1: TAVR with a Next Generation Device: Multiple Repositioning and Less Paravalvular Aortic Regurgitation?

Presenter: Hans Figulla

October 28, 2013

Presentation TCT 2013

Annulus Sizing Using MSCT Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Presenter: Jonathon Leipsic

October 28, 2013

News Conference News TCT 2013

Long-Term Outcomes, Cost May Influence Use of TAVR in Moderate-Risk Patients

October 28, 2013

News Industry News

Boston Scientific Receives CE Mark For Lotus™ Valve System

October 28, 2013

News Industry News

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

October 28, 2013

Presentation TCT 2013

Mitral Regurgitation

Presenter: John Webb

October 27, 2013

News Daily News

TAVR Patients with Moderate/Severe Mitral Regurgitation Carry Worse Prognosis

October 11, 2013

News Daily News

Los Pacientes TAVR con Regurgitación Mitral Moderada/Severa tienen un Peor Pronóstico

October 11, 2013

Presentation

Interplay Between Mitral Regurgitation and TAVR with CoreValve

Presenter: F. Bedogni

October 07, 2013

News Daily News

Meta-analysis: Women Fare Better Than Men After TAVR Despite More Complications

Yael L. Maxwell

September 27, 2013

News Industry News

Boston Scientific Reports Favorable Six-Month Results from Lotus™ Valve System Clinical Trial

September 17, 2013

News Conference News ESC 2013

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

September 09, 2013

News Conference News ESC 2013

PARTNER A: TAVR the Optimal Choice for Diabetic Patients at High Risk

Yael L. Maxwell

September 04, 2013

Advertisement

Echocardiographic Results in the CoreValve US Extreme Risk Study: Hemodynamics and Aortic Regurgitation

Opportunities Exist to Improve Outcomes in Transapical TAVR

Mitral Regurgitation in Aortic Stenosis: How Often Is Surgical or Transcatheter Aortic Valve Replacement Effective?

Epidemiology and Prognostic Impact of Mitral Regurgitation (and Why Does MR Take a Backseat to Aortic Stenosis?)

Reduces Paravalvular Regurgitation

Incidence, Predictors, and Outcomes of Paravalvular Regurgitation After TAVR

Endoluminal Sciences: A New Concept for Eliminating Paravalvular Regurgitation

Case 1: TAVR with a Next Generation Device: Multiple Repositioning and Less Paravalvular Aortic Regurgitation?

Annulus Sizing Using MSCT Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Long-Term Outcomes, Cost May Influence Use of TAVR in Moderate-Risk Patients

Boston Scientific Receives CE Mark For Lotus™ Valve System

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

Mitral Regurgitation

TAVR Patients with Moderate/Severe Mitral Regurgitation Carry Worse Prognosis

Los Pacientes TAVR con Regurgitación Mitral Moderada/Severa tienen un Peor Pronóstico

Interplay Between Mitral Regurgitation and TAVR with CoreValve

Meta-analysis: Women Fare Better Than Men After TAVR Despite More Complications

Boston Scientific Reports Favorable Six-Month Results from Lotus™ Valve System Clinical Trial

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

PARTNER A: TAVR the Optimal Choice for Diabetic Patients at High Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content